In 2015, Ortmann et al. (31) reported that the order in which JAK2 and TET2 mutations were acquired in patients with myeloproliferative neoplasms influenced clinical features and the response to targeted therapy, which give us a hint that the sensitivity of PDAC at different stages to adjuvant chemotherapy may stem from the difference of key drivers and mutation order, which shape certain characteristics of early-stage and advanced PDAC. Here, TET2 is linked to myeloproliferative disorder.